

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

DLM8

RRID:CVCL_6669

Type: Cell Line

Proper Citation

RCB Cat# RCB1450, RRID:CVCL_6669

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6669

Proper Citation: RCB Cat# RCB1450, RRID:CVCL_6669

Description: Cell line DLM8 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse osteosarcoma

Defining Citation: [PMID:9579581](#), [PMID:26018200](#), [PMID:26320182](#)

Comments: Characteristics: Highly metastatic to lung (PubMed=9579581).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: DLM8

Synonyms: Dunn LM8, LM8

Cross References: CLO:CLO_0050199, RCB:RCB1450, Wikidata:Q54902749

ID: CVCL_6669

Vendor: RCB

Catalog Number: RCB1450

Hierarchy: cvcl_w629

Record Creation Time: 20220427T215819+0000

Ratings and Alerts

No rating or validation information has been found for DLM8.

No alerts have been found for DLM8.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Vickers ER, et al. (2026) Histotripsy treatment reduces tumor burden and extends survival in an orthotopic mouse model of osteosarcoma. *Frontiers in oncology*, 16, 1807753.

Zhang T, et al. (2026) A remove-remodel-repair strategy enabled by a spatiotemporally controlled hydrogel for integrative osteosarcoma therapy. *Biomaterials*, 336, 124484.

Bertho A, et al. (2025) Carbon minibeam radiation therapy results in tumor growth delay in an osteosarcoma murine model. *Scientific reports*, 15(1), 7305.

Hu X, et al. (2025) TCF19/CDKN2A Regulates Glycolysis and Macrophage M2 Polarization for Osteosarcoma Progression. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(7), e70519.

Lu H, et al. (2024) Photothermal Catalytic Reduction and Bone Tissue Engineering Towards a Three-in-One Therapy Strategy for Osteosarcoma. *Advanced materials (Deerfield Beach, Fla.)*, 36(40), e2408016.

Riquelme MA, et al. (2024) Antibody-activation of connexin hemichannels in bone osteocytes with ATP release suppresses breast cancer and osteosarcoma malignancy. *Cell reports*, 43(7), 114377.

Hay AN, et al. (2023) Ablative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Model. *Biomedicines*, 11(10).

Yui Y, et al. (2022) Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma. *International journal of cancer*, 151(5), 739.

Kinoshita H, et al. (2021) The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression. *Anticancer research*, 41(10), 4947.

Hennessy M, et al. (2021) Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma. *International journal of cancer*, 148(8), 1928.

Ideta H, et al. (2021) Antitumor Effect of Sclerostin against Osteosarcoma. *Cancers*, 13(23).

Wijesekera DPH, et al. (2020) Manipulation of the tumor microenvironment by cytokine gene transfection enhances dendritic cell-based immunotherapy. *FASEB bioAdvances*, 2(1), 5.

Yoshida K, et al. (2020) Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. *BMC cancer*, 20(1), 25.